Keros Therapeutics reports Q3 EPS ($1.41), consensus ($1.28)
The Fly

Keros Therapeutics reports Q3 EPS ($1.41), consensus ($1.28)

Reports Q3 revenue $388,000 vs. $8.000 last year. “This continues to be a year of clinical execution for Keros. In the third quarter, we completed enrollment ahead of schedule in our Phase 2 TROPOS trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension,” said Jasbir Seehra, chair and CEO. “This has set the stage for upcoming clinical data updates from our three clinical assets, which are expected over the next nine months.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App